Ceronco Biosciences

Ceronco is developing new anti-cancer drugs based on the SCS-technology. This technology improves delivery of drugs into the cancer cell through targeting the tumour cell membrane, enhancing the uptake and efficacy of drugs. The lead compound is CB001, a liposomal doxorubicin enriched with SCS’s. Additional development candidates have been identified, broadening the portfolio of new drugs to be developed based on the technology.